← Back to all trials
Terminated
NCT03333551
Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy
Conditions: Cardiac Amyloidosis
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE4
Enrollment: 4
Sponsor: Medical College of Wisconsin
Location: Medical College of Wisconsin Milwaukee Wisconsin
Summary
This is a pilot study designed to assess for relative change in cardiac 18F Florbetapir uptake in patients with AL cardiac amyloidosis after appropriate chemotherapy.
Eligibility Criteria
Inclusion Criteria:
1. Patients aged \> 18 years are eligible.
2. Patient must provide informed consent to participate in the study protocol.
3. All patients must have clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or cardiac MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis).
4. Planned plasma cell-directed chemotherapy.
5. A negative pregnancy test will be required for all women of child bearing potential, breast feeding is not permitted.
6. Patients must be able to undergo PET-CT imaging
7. Patients must be able to complete 6-minute walk test
Exclusion Criteria:
1. Severe claustrophobia
2. Pregnancy
3. Allergy to F-18 florbetapir
Source: ClinicalTrials.gov (NCT03333551). StuddyBuddy aggregates publicly available trial information.
